Purpose: Anterior thalamic deep brain stimulation (ATN DBS) is an emerging, effective treatment for patients with drug-resistant epilepsy, but long-term results on its efficacy and safety are lacking. To evaluate the long-term efficacy and safety of ATN DBS treatment, as well as predictors of its success, in patients with drug-refractory epilepsy (DRE). Method: We retrospectively studied clinical outcomes in 29 consecutive refractory epilepsy patients treated by a single DBS team (two neurosurgeons, four neurologists) over an 11-year period, for whom follow-up was performed for up to 137 months (mean, 74.9 months). Results: The average participant was 30.7 (AE10.4) years old and had epilepsy for 19.3 (AE9.0) years. The mean preoperative frequency of disabling partial or generalized tonic-clonic seizures was 27.5 (AE8.6, SE) seizures a month. The median percent seizure reduction was 71.3% at 1 year, 73.9% at 2 years, and ranged from 61.8% to 80.0% over post-implant years 3 through 11 in the long-term study (overall 70% median reduction). In the 11-year study period, 13.8% (4/29) of subjects were seizure-free for at least 12 months during this time. There was only one symptomatic intracranial hemorrhage that happened during followup (3.4%). Infection requiring removal and later re-implantation of hardware occurred in only 1 of 30 patients (3.3%), who was subsequently excluded from our follow-up assessment. Hardware malfunction including lead disconnection occurred in 2 of 29 cases (6.9%). Revision of lead position to redeem poor clinical response was performed in 3 of 58 implanted leads (5.2%). Conclusions: ATN DBS can be an effective therapy in a variety of patients with DRE. Importantly, we provide evidence that significant therapeutic efficacy can be sustained for up to 11 years. Neurological complications were rather rare, but long-term hardware-related complications should be followed arrectis auribus.
Introduction
Despite the introduction of modern anti-epileptic drugs (AED), approximately 30% of patients continue to have refractory seizures that adversely affect their quality of life [1, 2] . Electric modulation of epileptic neural circuits via an implanted neuro-stimulator system, including deep brain stimulation (DBS), has been recognized as a promising alternative therapeutic choice for patients with epilepsy [3] [4] [5] [6] . Among various neural targets for DBS, the anterior nucleus of the thalamus (ATN) is a central node in the Papez circuit [7] . It receives input from the mesial temporal areas via the fornix, and has efferent connections to the ipsilateral cingulate, antero-mesial frontal and temporal lobes [8] . Although the mechanistic underpinnings of the anti-seizure efficacy of DBS remain unclear, modulation of the ATN with DBS is an attractive option for patients with drug-refractory epilepsy (DRE).
Long-term follow-up data for epilepsy patients treated with DBS is scarce. Very recently, long-term efficacy and safety data from the SANTE trial (Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy) was released, with this stimulation treatment showing sustained efficacy and safety in a treatmentresistant population [9] . In the present study, we report a retrospective analysis of seizure outcomes conducted to analyze the efficacy and safety of ATN DBS for drug-refractory patients at our institution since the first implant was placed in 2005, and examine predictors of ATN DBS treatment success. In addition, we sought to investigate the long-term cognitive changes resulting from chronic ATN DBS.
Patients and methods

Study design
The data used in the present study were collected via retrospective review of the medical records of 30 consecutive patients with DRE who were treated with ATN DBS by our neuromodulation team. DBS surgery was administered to these patients by two neurosurgeons (KJ Lee and BC Son) and four neurologists (SH Kim, SC Lim, J Kim and YM Shon) at 2 Catholic University Hospitals (Yeouido St. Mary's and Seoul St. Mary's Hospital) over an 11-year period [10] [11] [12] .
Patients
Our criteria for bilateral ATN DBS implantation have been published previously [12] : frequent (>4 per month) and disabling seizures not controlled by multiple AED treatment modalities; not a candidate for resective surgical treatment as determined by video-EEG monitoring (e.g. multifocal ictal onset zone); previously failed resective or disconnection surgery; patients (or caregivers) agreed to keep a daily seizure diary for a 3-month baseline period before DBS implantation and continuously after initiation of treatment; patients (or caregivers) agreed that no changes to the baseline presurgical medication regimen would be made during at least the first year after DBS implantation. The study was conducted with the approval of the Institutional Review Board (SC11OISI0013) of the Catholic University of Korea, and informed written consent was obtained from all patients or from their family members.
Thirty consecutive patients who underwent ATN DBS treatment for DRE between 2005 and 2015, and who had follow-up evaluations for more than 1 year, were included. Follow-up evaluations were conducted during routine outpatient clinic visits, hospital visits for reoperation or scheduled battery changes, and via phone interviews.
Surgical technique and programming of device
Each patient underwent frame-based, microelectrode-guided, stereotactic implantation of DBS leads (model 3389 or 3387; Medtronic 1 Inc., Minneapolis, Minnesota, USA). The cost of the surgeries were mostly reimbursed by Korean national healthcare insurance. ATN implantation was performed with either local or general anesthesia using a Leksell frame. We targeted the ATN on the parasagittal magnetic resonance imaging (MRI) as a prominence in the inferior wall of the lateral ventricle. The insertion of DBS electrodes (model 3387 or 3389; Medtronic 1 Inc.) and implantable pulse generators (IPGs, model Soletra or Activa SC; Medtronic 1 Inc.) was performed as previously described [10, 13] .
We confirmed electrode placement within the ATN with postoperative imaging -either brain CT (21 patients) or MRI (9 patients). Activation and programming of the IPGs started 1 or 2 weeks after implantation. The initial parameters were similar to the parameters used for surgery for movement disorders (high frequency of 130 Hz; pulse width of 90 microseconds; continuous stimulation). Using a previously reported programming algorithm [12] , the relatively low voltage (1.5 $ 3.1 V) stimulation and monopolar configuration were adjusted on the basis of improvement in seizure frequency and minimizing side effects.
Variables to be assessed
Long-term follow-up and adjustment of DBS parameters were conducted by the authors (YM Shon, SH Kim and J Kim). Retrospective chart review was performed to collect follow-up and outcome data. All patients had the opportunity to have DBS therapy for at least one year. The following data were collected from the last available clinical follow-up: mean weekly seizure frequency (from seizure diaries kept by patient or caregivers), adverse effects (AEs) of DBS therapy, stimulation parameters, changes in antiepileptic drug regimens (if used), the timing of replacing dead IPGs, and reason for revisions of DBS devices. We categorized patients with a !50% median decrease in seizure frequency for each 3-month period compared to the pre-implant baseline as responders, and patients with a <50% decrease in median seizure frequency as non-responders. The sources of the data included outpatient clinic visits, medical record review, and telephone interviews.
To limit the bias created by non-responder attrition, we computed follow-up duration using a last observation carried forward (LOCF) analysis instead of a declining-n analysis [3] . In addition, we included only patients who had at least 1 year of follow-up after initiation of ATN DBS and who had reliable documentation of long-term seizure frequency. The neuropsychological (NP) testing protocol has been previously described in detail [12] . We only included data from subjects without mental retardation (IQ >70), ensuring an adequate IQ for comprehensive baseline NP testing, and for whom follow-up examination was performed at least one or more years after initiation of treatment.
Statistical methods
Statistical analyses of quantitative variables were performed with a dedicated software package (SPSS version 14.0; SPSS Inc, Chicago, Illinois, USA). If a missed follow-up visit resulted in lack of a data point, the patient was excluded from analysis for that year. We used Student's t-tests and one-way ANOVA tests for comparison of continuous variables, and Chi-square tests for categorical variables. Statistical tests were 2-tailed, and p-values < 0.05 were considered to be statistically significant. For the seizure frequency data, median seizure reduction at each time point was calculated for the whole cohort and compared with the baseline seizure frequency using the Wilcoxon signed-rank test.
Results
Participant demographics and clinical data
Beginning in 2005, we performed ATN DBS in 30 consecutive patients with DRE. Twenty-nine patients were included in the long-term treatment analysis. One patient (3.3%) withdrew two months after surgery due to implant site infection, and removed all DBS devices.
The patients' demographic data are presented in Table 1 . The mean age of the 29 patients was 30.7 AE 10.4 years; 62.1% (18 subjects) were male. The mean duration of epilepsy was 19.3 AE 9.0 years, and most patients were undergoing AED polytherapy (4.3 AE 2.7 regimens) and had failed several AEDs (5.2 AE 4.1 drugs) in the past ( Table 1 ). The patients' mean age at symptom onset was 11.9 AE 8.6 years, and the median age at surgery was 29 years (range, 15-55 years). The patients were followed for a median of 70 months (5.8 years; range, 18-137 months).
Seizure outcome and follow-up data
Of the 29 patients in our analysis, 26 patients completed at least 2 years of follow-up, 24 completed 3 years, 20 completed 5 years, 12 completed 7 years, 10 completed 9 years and 2 completed 11 years. There were eight discontinuations of stimulation in the long-term follow-up period, including four deaths (see 'Death' in the result section below), three due to lack of efficacy, and one due to complaints of increased agitation despite his meaningful seizure reduction.
Long-term clinical efficacy of ATN DBS
The evolution pattern of patients' median seizure reduction is presented in Fig. 1 . Patients experienced a median reduction of disabling seizure frequency of up to 70.0%. This response continued consistently for more than 11 years. The median percent seizure reduction (compared to the baseline frequency) at years 1 through 11 were 70.0% (range, À20-100%), 73.6% (range, À87.5-100%), 78.4 (range, 8.3-100%), 70.8% (range, 25-100%), 70.9% (range, À5.6-100%), 70.8% (range, 0-100%), 66.7% (range, À5.6-100%), 68.4% (range, À25-100%), 66.7% (range, À5.6-100%), 66.7% (range, 10-100%), and 66.7% (range, 40-83.5%), respectively. This therapeutic efficacy was statistically significant for years 1 through 11 (p < 0.001). The rate of reduction in seizure frequency was similar in participants who had changes in their AED regimen (n = 18) and those who did not (n = 11).
In addition, 24.1% of participants (7/29) were seizure-free at least 6 months, and some (4/29, 13.8%) had extended periods of seizure freedom at least 1 year or longer. No participants were seizure-free over the entire follow-up period. The distribution of responders is shown in Fig. 2 . Overall, 76% of patients (22/29) were responders during the follow-up period: 80.8% (21/26) at 3 years, 85% (17/20) at 4 years, and 75.0% (12/16) at 6 years, 70% (7/10) at 8 years, and 66.7% (2/3) at 10 years (Fig. 2) . Seven patients did not get a significant benefit in seizure reduction with ATN DBS and were categorized as non-responder. In two of these patients, the DBS system was explanted because of lack of efficacy.
Subgroup analysis
Median seizure reduction was also compared by separating patients according to their epilepsy syndrome: those with seizures that had a temporal lobe onset (9 patients), frontal lobe onset (8 patients) , and all other onset regions (multifocal or generalized onset; 12 patients). The median reduction in seizure frequency was 71.5% at 1 year (n = 9, p < 0.001) and 70.0% at 7 years (n = 3, p < 0.001) for temporal lobe seizures, and 74.1% at 1 year (n = 8, p < 0.001) and 83.9% at 10 years (n = 3, p < 0.001) for frontal lobe seizures. Patients with the remaining seizure onset locations experienced a median reduction of 42.6% at 1 year (n = 12, p < 0.05) and 67.6% at 10 years (n = 3, p < 0.01). Moreover, patients with temporal and frontal lobe seizures had the tendency to display more favorable responses to ATN DBS therapy when compared to those with multifocal or generalized onset at postoperative 1 year (p = 0.093). However, the long-term outcomes were not different among the three groups (p > 0.05), with all groups showing favorable results (Fig. 3) .
None of the demographic data including age at the onset of epilepsy, duration of epilepsy, age at the DBS operation, presence of structural lesions, number of failed AEDs, prior failed epilepsy surgery, or accompanying developmental delay, predicted a poorer response to ATN DBS therapy.
Neuropsychological outcome
Post-operative NP assessments were performed after more than 1 year (mean 14.2 AE 4.9 months) after the ATN DBS operation. Of the 19 patients who completed baseline or follow-up NP testing after implantation, 12 patients were included in the final analysis. Reasons for exclusion included a considerable cognitive derangement due to mental retardation (3 patients), the completion of only one session of NP testing (3 patients), and a failure to be tested during the pre-operative period (1 patient). The selected NP testing results from the 12 included patients are presented in Table 2 . Results were definitely favorable for not only immediate (p < 0.05), and delayed verbal memory (p < 0.01), but also for full memory quotient (p < 0.05). In addition, a significant improvement was observed in word fluency tasks (letter and category, p < 0.05) after long-term ATN DBS. There were no significant changes in general abilities (IQ, MMSE), information processing, or executive function.
Adjustment of AED therapy
AEDs were prudently adjusted only after the 2nd year of followup, if necessary. Not surprisingly, non-responders were more likely to add a medication; 9.1% of the responders (2/22) and 71.4% of the non-responders (5/7) had at least one new AED added (p < 0.05). However, a similar reduction in seizure frequency was seen for subjects who had at least one medication added compared to those subjects who did not add an AED. Twenty-two percent (5/22) of the responders and 14.3% (1/7) of the non-responders had a reduction in the dosage or number of AEDs. No significant link was observed between choosing a specific AED and seizure control.
Complications of therapy
The most frequent device-related AE at any time after insertion was implant site pain (34.4%, 10/29 patients). In all but a few cases, this resolved spontaneously over the course of a few months. Unpleasant sensory changes, including tingling, vibration, or shocking sensations, at the device implantation site were observed in 27.6% of patients (8/29), but it was tolerable enough that none of these patients had to discontinue their therapy during the followup period. The cardinal AEs are described below.
Infection
Postoperative deep infection developed in one of the initial patients (3.3%, 1/30) requiring device removal, intravenous antibiotic treatment, and subsequent exclusion from our longterm follow-up. Among the remaining 29 patients enrolled, only one patient (3.4%) experienced a superficial infection in the wound site on the left anterior chest, and short-term antibiotic therapy was sufficient for the patient's full recovery.
Intracranial hemorrhage
Intracranial hemorrhage was observed in one patient (3.4%), who experienced left hemiparesis (upper extremity predominant) immediately after DBS lead insertion on the right side. However, this weakness completely disappeared after 3 months with intensive physical therapy.
Revision of lead location
In three patients, one of two DBS leads was not within the ATN target. One patient returned to the operating room the day after the first surgery to revise the lead position. However, the other two patients underwent lead reposition surgery more than one year after the initial operation. The former subject was seizure free for >2 years at the last follow-up visit. However, the latter two did not experience a significant seizure reduction after revision. There were no additional complications related to the surgeries to reposition the leads, and the overall incidence of lead revision for malposition was 5.2% (3/58 implanted leads). 
Lead fracture or hardware malfunction
Two patients (6.9%) had to return to the operating room to replace a fractured lead (very high impedance measured at all DBS electrodes) or disconnected systems. However, the long-term outcomes of these patients were not statistically different from those of the rest of the study population.
Depression & suicide
Depression events were experienced in five patients (17.2%) at some time after the implant surgery, and seven episodes from three subjects were considered to be device-related. Among the five subjects who reported depression, 60% (3/5) had a history of depression. All of five patients consulted to psychiatric department and followed up for their proper treatment of symptom, during follow-up period of DBS therapy. After implantation, 6.9% of patients (2/29) reported at least one instance of suicidal ideation. One subject (3.4%) committed suicide approximately 7.5 years after implantation, not judged by the site investigator nor the data monitoring committee to be device-related.
Subjective memory impairment
Subjective memory impairment was reported in seven subjects (24.1%) at some time during the follow-up period, but none of the episodes were considered to be serious. Among these patients, five performed both baseline & follow-up NP testing, and only one patient had a confirmed change from baseline in the verbal memory domain. It did not appear that memory impairment was linked to the pattern of seizure control or to any particular stimulation parameter.
Deaths
During the follow-up period, there were four deaths. One (3.4%) probable sudden unexplained death in epilepsy (SUDEP) occurred 5 years after implantation. The remaining three deaths were due to suicide, cardiorespiratory arrest from septic shock from a nonneurological cause, and severe intracranial hemorrhage from a traffic accident.
Discussion
Key results
In the present study, we analyzed the efficacy of ATN DBS for controlling disabling seizures in 29 patients with drug-refractory epilepsy (DRE) who were followed by single team over an 11-year period. We found that ATN DBS demonstrates robust therapeutic efficacy in patients with DRE, as evidenced not only by the reduced frequency and severity of seizures, but also by meaningful postprocedural cognitive improvement. These therapeutic effects were statistically significant and durable, with responses maintained for up to 11 years. ATN DBS worked well for various types of focal epilepsy syndrome, but was not affected by AED adjustment.
The most frequently reported side effects were pain or discomfort at the implant site, subjective memory impairment, & depressive mood. However, during follow-up most of these side effects disappeared spontaneously or shortly afterwards. Serious complications causing device removal or permanent brain injury were rare (3.3%).
Clinical efficiency of long-term ATN DBS
Results of the present study support and extend the findings of previous studies, which demonstrated that ATN DBS provided a significant and sustained reduction in seizure frequency in adults with chronic epilepsy that were resistant to multiple AEDs, and in many cases to vagus nerve stimulation (VNS) or epilepsy surgery [5, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Fisher et al. performed a randomized, active-control trial of 110 patients with localization-related epilepsy (Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy [SANTE] ) and reported a median reduction in seizure frequency of 40.4% in the stimulated group compared with 14.5% in the control group at the end of the blinded phase (3 months) [14] . During the follow-up, an open-label study for more than 5 years was available for 83 of 110 patients; the median seizure reduction and responder rate at 5 years was 69% and 68%, respectively. In addition, 16% of subjects were seizure-free for at least 6 months [9] . Recently, Krishna and colleagues observed 11 patients who experienced a >50% reduction in seizure frequency after ATN DBS; however, among the patients who underwent long-term follow-up, only 37.5% (3/8) had a >50% reduction in seizure frequency [18] .
Our group has already demonstrated the clear efficacy of ATN DBS for not only reducing seizure frequency [10] , but for providing improvement in verbal recall and oral information processing, which may be related to the bilateral activation of the frontolimbic circuit [12] . Moreover, an earlier long-term outcome study of ours with 15 intractable epilepsy patients (mean duration, 39 months) showed the possibility of a short-term therapeutic effect which convincingly reflects the long-term outcomes [11] . In the present study, which had a doubled population through the addition of subsequent patients, nearly 70% of patients experienced a meaningful reduction in seizure burden. Our results (a median seizure reduction of 70%) are similar to those reported in not only the previous non-randomized studies (11.5-75.6% reduction) [12, 17, 18, 20, 21] but also to those reported in a recent, long-term, randomized trial (the SANTE trial) [9] . In addition, we found a trend towards more favorable short-term outcomes in patients with a temporal or frontal seizure origin compared to those with a more diffuse ictal onset [9] , but the small sample size and heterogeneity of the patient population hampered the interpretation of its clinical implication.
Despite previous trials to find the optimal therapeutic conditions for ATN DBS, very few predictors of its efficacy have been coherently identified in the literature. First of all, accurate targeting of DBS electrodes is a sine qua non for the optimal therapeutic efficacy of ATN DBS, similar to other functional neurosurgical procedures. Although the theoretical stereotactic coordinates for the ATN are 12 mm superior, 5-6 mm lateral, and 0-2 mm anterior to the mid-commissural point [22] , large variations exist in its real location in stereotactic space [18, 23, 24] . Therefore, targeting of the ATN based on direct visualization by MRI may be a more reliable method than that relied on for indirect targeting. Some previous studies have suggested that the best target point may be the superior anterolateral area [24] or inferolateral area [18] which correspond to the anteroventral part within the ATN boundary. However, the very small and heterogeneous patient population in this study precluded achieving a hot-spot within the ATN with a prognostic significance. Second, the SANTE trial reported a decrease in seizure frequency in the sham group (20% decline at 1 month; 14% at 3 months, microthalamotomy effect) [14] . Krishna et al. recently raised the possibility of using the insertional effect as a barometer for longer-term therapeutic efficacy [18] . They observed an insertional effect in 56% of patients, and it was sustained for 2-4 months; however, the detailed nature of an insertional effect from lesioning at the ATN has not been elucidated in most of the previous studies, including ours [9, 11, 17, 21] .
Neuropsychological changes from long-term ATN DBS
In agreement with our previous study [12] , we found that ATN DBS induced a significantly favorable effect on not only immediate or delayed verbal memory (p < 0.01) but also the word fluency tasks (letter and category, p < 0.05), after at least 1-year of continuous treatment in twelve patients.
We can hypothesize several underlying mechanisms for the beneficial effects on cognition caused by ATN DBS. First, we hypothesize that ATN DBS achieves its effects in part through modulation of the mesial temporal cortex by way of the Papez circuit [7] . This hypothesis may be supported by a recent study that involved bilateral ATN stimulation of the rat brain. There was reversibly increased glucose uptake in the connected thalamic nuclei and both hippocampi, which might be attributable to excitation of efferent thalamo-hippocampal projections from the ATN [25] . Second, a recent large animal study showed that ATN DBS may activate extratemporal areas, such as the prefrontal, orbitofrontal, motor, somatosensory, and insular cortices, and eloquent cortical areas, as illustrated by increased BOLD at fMRI [26] . These results may be relevant to the favorable therapeutic efficacy of ATN DBS in patients with frontal lobe and multiregional origin epilepsy (median seizure reductions of 69.0% and 58.2%, respectively) seen in our study, which was not significantly dissimilar to the efficacy seen in patients with a temporal lobe origin (77.6%).
In a long-term follow-up report from the SANTE trial [9] , the authors stated both similar (meaningful improvement of executive function or attention), and dissimilar (no significant changes in verbal or visual memory) findings in comparison to our results. This discrepancy may be attributed to several factors. First, we used continuous stimulation rather than the cyclic mode (1 min on, 5 min off) used in the SANTE trial. Even during NP testing, all patients were still receiving stimulation in the ATN in our study. Second, our study population is somewhat heterogeneous and different from that of the SANTE trial; we included patients suffering from multiple ictal sources with a posterior predominant nature (11/29, 37 .9%) and one patient with Lennox-Gastaut syndrome. Third, our patients were not evaluated by an annual iterative NP testing battery. The results of the SANTE trial may be inevitably affected by a "learning-effect" during annual NP testing, which can result in abstruse data, making it difficult to figure out the actual change that results from DBS.
Complications, retention rate of chronic ATN DBS
ATN DBS was relatively safe over time, and most AEs happened at the early post-operative period after implantation. Although pain or sensory change associated with the implanted device were relatively common (34.4% and 27.6% of patients, respectively), these symptoms abated spontaneously within a few weeks or months.
SANTE results showed a high prevalence of depression after stimulation not only during the blinded phase (14.8%) but also during long-term follow-up (37.3%), which are much higher than our results (17.2%) [9, 14] . We hypothesize that this discrepancy could be related to the broader inclusion criteria for ATN DBS implantation (i.e., inclusion of patients with mental retardation and generalized epilepsy) and the much smaller sample size used in our study compared with the SANTE trial. Interestingly, we found about a fourth of patients (7/29) complained of a subjective decrease in memory. However, only a minor portion of patients (1/ 5 subjects) actually experienced, objective cognitive impairment. Salanova et al. showed similar findings in some subjects who reported mood and memory problems after ATN DBS. The patients showed improved attention, executive function, depression, mood disturbance, and subjective cognitive function compared with baseline. The authors advocated a further study to determine if there are individual risk factors predisposing subjects to the emergence or worsening of depression and cognition problems during ATN DBS [9] .
For the long-term follow-up after device implantation (median, 70 months), our subjects showed a high retention rate of 72.4%, and only another four patients (13.8%) were dissatisfied with the efficacy of ATN DBS and dropped out of the long-term follow-up. Our data suggests that ATN DBS was well tolerated in refractory patients, and favorably comparable or superior to the optimal AED therapy which leaves patients inevitably vulnerable to medicationrelated side effects, such as neurovegetative symptoms (dizziness, sedation, nausea/vomiting, and hormonal dysregulation) and idiosyncratic skin reactions [27, 28] .
Limitations
The non-randomized nature of our analysis and the fact that the therapy was performed in an uncontrolled, open-label manner are both limiting factors of this study. As the clinical outcome data are based on a retrospective review of clinic charts and available seizure diaries, measurement or selection biases (secondary to loss of follow-up), which may distort the results in the optimistic direction, do not pose a risk. The composition of our patients was not homogeneous, and one patient with generalized epilepsy was included. The outcomes for these patients with various epilepsy syndromes may be different; however, the small sample size did not allow us to discriminate these subgroup differences. The small number of our patients who underwent ATN DBS also limited the power of this study (i.e. temporal lobe epilepsy vs. frontal lobe epilepsy, p > 0.05).
Another potential confounding variable is the effect of AED regimen changes, which were not standardized in our case series, on seizure frequency. We maintained almost all patients on their baseline AED dose from the immediate postoperative phase to at least the first year after implantation [12] . Instead of using a declining-n analysis, we intended to lessen the inaccuracy in assessing seizure reduction of our patients by using an LOCF analysis, which is more representative of actual DBS efficacy in our population. However, the LOCF analysis has implicit limitations and is not always a 'conservative' approach. If many patients drop out when they show an excellent therapeutic response, LOCF tends to give a high estimate of success [29] .
A final important potential confounding factor is the contrasting stimulating parameter (SP) of our group, which consisted of low intensity (1.5 $ 3.1 V), variable pulse width (90 $ 150 msec), and frequency (100-185 Hz). The majority of previous epilepsy studies investigating DBS [14, [16] [17] [18] 21] have administered the stimulation using a cyclic mode at 90 msec, 145 Hz, & relatively high intensity (i.e., 5 V). Despite the clinical application of DBS for more than three decades now, the SPs of DBS for epilepsy are programmed only empirically and the standardization of the optimal settings for anti-seizure efficacy is lacking. A recent, intriguing report postulated a preference for the lower intensity, wider pulse width, and continuous mode method of stimulation, rather than conventional cycling mode, for ATN DBS [30] . It is still unclear whether our favorable therapeutic efficacy and high retention rate during long-term follow-up were linked to the characteristics of our SPs. Further multidisciplinary investigations will be needed to elucidate the underlying mechanism of ATN DBS according to optimal SPs, which account for its therapeutic implications against intractable epilepsy.
Conclusion
Despite having very little knowledge of the mechanisms underlying DBS effects in the treatment of epilepsy, long-term ATN DBS was confirmed to be well-tolerated and associated with not only a significant and sustained reduction in the frequency and severity of seizures, but also with a favorable effect on cognition in a selected group of patients with DRE. Further investigation of the mechanisms of ATN DBS and its optimal SPs will lead to better understanding and identification of patient-specific, best target locations, as well as the universal characteristics of patients suitable for ATN DBS treatment.
